新生血管性年龄相关性黄斑变性抗VEGF转换治疗:自动化视网膜液体容积分析洞察
本回顾性研究纳入186眼新生血管性年龄相关性黄斑变性(nAMD),在至少3次贝伐珠单抗注射反应不佳后转换为雷珠单抗或阿柏西普。使用基于人工智能的Notal-OCT分析仪量化视网膜液体,发现早期转换者(3-5次注射)转换后总视网膜液体从158 nL降至20 nL(P<0.001),而晚期转换者(≥6次注射)在贝伐珠单抗后和转换后均显示液体减少。最佳矫正视力变化无统计学意义。
要点
- 早期转换者贝伐珠单抗后总视网膜液体从105 nL增至158 nL,转换后降至20 nL(P<0.001)。
- 晚期转换者贝伐珠单抗后和转换后总视网膜液体均减少(P<0.001),色素上皮脱离体积也减少(P=0.007)。
- 中央亚区厚度仅在早期转换者中显著改善(P=0.004),视力变化无统计学意义。
核心结论
- 自动化液体分析可可靠量化nAMD治疗反应,早期转换者贝伐珠单抗后恶化而晚期转换者部分反应,支持个体化数据驱动治疗策略。
研究设计与样本
- 回顾性研究纳入186眼nAMD,至少3次贝伐珠单抗注射反应不佳后转换为二线抗VEGF药物,分为早期转换者(3-5次注射)和晚期转换者(≥6次注射)。
主要发现
- 早期转换者总视网膜液体从105 nL增至158 nL后转换后降至20 nL(P<0.001),色素上皮脱离体积转换后减少(P=0.010)。
- 晚期转换者贝伐珠单抗后和转换后总视网膜液体均减少(P<0.001),色素上皮脱离体积减少(P=0.007)。
- 中央亚区厚度仅在早期转换者中显著改善(P=0.004),视力变化无统计学意义。
临床怎么用
- 自动化OCT液体分析可用于量化nAMD抗VEGF转换治疗的反应,辅助识别早期与晚期转换者的不同液体变化模式。
局限性
- 需前瞻性研究确认对患者结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in neovascular age-related macular degeneration (nAMD) using automated volumetric retinal fluid analysis. METHODS: This retrospective study included 186 eyes with nAMD showing inadequate response after ≥3 bevacizumab injections. Patients were switched to a second-line anti-VEGF agent and categorized as early (3-5 injections) or late (≥6 injections) switchers. Optical coherence tomography (OCT) scans were analyzed using the Notal-OCT Analyzer (NOA), an AI-based algorithm for retinal fluid quantification. Parameters included total retinal fluid (TRF), intraretinal fluid (IRF) volume, subretinal fluid (SRF) volume, pigment epithelial detachment (PED) volume, central subfield thickness (CST), and visual acuity (VA), assessed at baseline, after bevacizumab, and after three injections of the new agent. RESULTS: Early switchers showed an increase in TRF from 105 nL to 158 nL after bevacizumab, then a reduction to 20 nL postswitch ( P < 0.001); PED volume decreased postswitch ( P = 0.010). Late switchers showed fluid reductions both after bevacizumab and postswitch (TRF: P < 0.001; PED: P = 0.007). CST significantly improved only in early switchers ( P = 0.004), while VA changes were not statistically significant. CONCLUSION: Automated fluid analysis reliably quantifies treatment response in nAMD. Early switchers showed worsening after bevacizumab, while late switchers had partial responses. These findings highlight the potential of automated analysis to support more individualized, data-driven treatment strategies. Prospective studies are required to confirm impact on patient outcomes.
引用
- Dor O, Cohen M, Shahar-Gonen M, et al. ANTI-VEGF THERAPY SWITCHING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Insights from Automated Volumetric Retinal Fluid Analysis. Retina. 2026. PMID: 41490049. doi:10.1097/IAE.0000000000004756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。